Oculis Holding AG
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OCS research report →
Companyoculis.com
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
- CEO
- Riad Sherif
- IPO
- 2021
- Employees
- 49
- HQ
- Zug, CH
Price Chart
Valuation
- Market Cap
- $1.60B
- P/E
- -13.61
- P/S
- 2491.42
- P/B
- 6.60
- EV/EBITDA
- -14.08
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -2889.37%
- Op Margin
- -16740.95%
- Net Margin
- -18861.29%
- ROE
- -57.09%
- ROIC
- -42.07%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-94,508,181 · -10.18%
- EPS
- $-1.81 · 14.62%
- Op Income
- $-79,145,361
- FCF YoY
- -30.97%
Performance & Tape
- 52W High
- $34.48
- 52W Low
- $16.00
- 50D MA
- $27.42
- 200D MA
- $22.85
- Beta
- 0.20
- Avg Volume
- 374.23K
Get TickerSpark's AI analysis on OCS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our OCS Coverage
We haven't published any research on OCS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate OCS Report →